Rapport Therapeutics (RAPP) CSO reports 8,500-share sale under 10b5-1 plan

Rhea-AI Filing Summary

David Bredt, Chief Scientific Officer of Rapport Therapeutics, Inc. (RAPP), reported sales of company common stock on 09/15/2025. The Form 4 shows two separate sale entries executed under a Rule 10b5-1 trading plan adopted on December 12, 2024: 5,098 shares sold at a weighted-average price of $23.8841 and 3,402 shares sold at a weighted-average price of $24.6583. The filing lists beneficial ownership amounts following the transactions as 421,544 and 418,142 shares respectively. The report was signed by an attorney-in-fact on behalf of the reporting person on 09/17/2025.

Positive

• Transactions executed under a Rule 10b5-1 trading plan, indicating pre-authorized trades
• Form 4 filed promptly and includes weighted-average prices plus an undertaking to provide per-price details upon request

Negative

• Insider sale of 8,500 shares (5,098 and 3,402 shares) which reduces officer ownership
• Beneficial ownership reported to have decreased (figures shown as 421,544 and 418,142 following transactions)

Insights

Securities Analyst

TL;DR: Officer sold 8,500 RAPP shares under a pre-established 10b5-1 plan; transactions were disclosed promptly by Form 4.

The sales total 8,500 shares executed on 09/15/2025 in two groups with weighted-average prices of $23.8841 and $24.6583. The use of a Rule 10b5-1 trading plan indicates the trades were pre-authorized on December 12, 2024, which typically reduces the likelihood of opportunistic timing. The Form 4 shows beneficial ownership figures after each reported transaction (421,544 and 418,142 shares), and the filing was signed by an attorney-in-fact on 09/17/2025. For investors, this is a routine insider sale disclosure rather than an operational update.

Corporate Governance Expert

TL;DR: Insider disposals were processed through an established 10b5-1 plan and properly reported.

The reporting person is identified as an officer (Chief Scientific Officer) and the filing documents that the transactions were executed pursuant to a Rule 10b5-1 plan adopted on December 12, 2024. The Form 4 includes the required weighted-average prices and an undertaking to provide per-price sale breakdowns upon request. The signature by an attorney-in-fact on 09/17/2025 is consistent with authorized filing practices. This filing meets disclosure requirements for officer trading activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Bredt David

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		S(1)		5,098	D	$23.8841(2)	421,544	D
Common Stock	09/15/2025		S(1)		3,402	D	$24.6583(3)	418,142	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.42 to $24.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.42 to $24.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

	/s/ Troy Ignelzi, Attorney-in-Fact	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did RAPP insider David Bredt report on Form 4?

The filing reports that David Bredt, Chief Scientific Officer, sold a total of 8,500 shares of Rapport Therapeutics common stock on 09/15/2025.

Were the sales executed under a trading plan?

Yes. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

What prices were the shares sold at?

The Form 4 reports weighted-average prices of $23.8841 for 5,098 shares and $24.6583 for 3,402 shares, with ranges noted in the filing.

How many shares does the filing show as beneficially owned after the transactions?

The filing lists beneficial ownership amounts following the reported transactions as 421,544 and 418,142 shares respectively.

Who signed the Form 4?

The Form 4 was signed by Troy Ignelzi, Attorney-in-Fact on behalf of the reporting person on 09/17/2025.